{"nctId":"NCT02829775","briefTitle":"A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies","startDateStruct":{"date":"2004-01"},"conditions":["Chronic Myelogenous Leukemia","Malignant Melanoma","Renal Cell Carcinoma"],"count":9,"armGroups":[{"label":"Interferon Alfa-2A in Cancer Participants","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated Interferon Alfa-2a","Drug: Recombinant Interferon Alfa 2a"]}],"interventions":[{"name":"Pegylated Interferon Alfa-2a","otherNames":["Pegasys"]},{"name":"Recombinant Interferon Alfa 2a","otherNames":["Roferon-A"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must have completed protocol NO15753, NO15764, NO16006 or NO16007 and responded to treatment at the end of the trial as defined in the parent protocol\n* CML participants must have a confirmed cytogenetic complete response within 2 months of entering the extension study. MM and RCC participants must have tumour assessments verifying stable or better response within 2 months of entering the extension study\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Refusal to use adequate contraceptive measures among men and women of childbearing potential","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; Life-threatening experience (immediate risk of dying); Persistent or significant disability or incapacity; and congenital anomaly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Overall Tumor Response","description":"Tumor response was assessed every 6 months using hematological evaluation or any other appropriate diagnostic techniques, as per standard of care practice. The complete response (CR) and partial response (PR) status were recorded from case report form.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":9},"commonTop":[]}}}